Article
A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association - 1 Nov 1996
Japour A J, Lertora J J, Meehan P M, Erice A, Connor J D, Griffith B P, Clax P A, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker C S
Abstract excerpt
A phase-I study was conducted to examine the safety, pharmacokinetics, and activity of combination 2',3'-dideoxyinosine (ddI) and ribavirin against human immunodeficiency virus type 1 (HIV-1)-positive individuals with CD4+ cell counts of < or = 500/microliter. Nineteen patients were enrolled into the study in which ddI monotherapy (200 mg p.o.b.i.d.) was administered for the first 4 weeks, followed by the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.